San Diego-centered Viking Therapeutics marked itself as a serious competitor in the weight loss drug current market in February following revealing promising information from the mid-stage trial of experimental drug VK2735, which advised it rivaled—and outperformed—Novo and Lilly drugs when given as being a weekly injection As well as in March